|
1
|
Kanda M and Kodera Y: Recent advances in
the molecular diagnostics of gastric cancer. World J Gastroenterol.
21:9838–9852. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2015. CA Cancer J Clin. 65:5–29. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Jemal A, Tiwari RC, Murray T, Ghafoor A,
Samuels A, Ward E, Feuer EJ, Thun MJ, et al: American Cancer
Society: Cancer statistics, 2004. CA Cancer J Clin. 54:8–29. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Perrotti D and Neviani P: Protein
phosphatase 2A: A target for anticancer therapy. Lancet Oncol.
14:e229–e238. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Junttila MR, Puustinen P, Niemelä M, Ahola
R, Arnold H, Böttzauw T, Ala-aho R, Nielsen C, Ivaska J, Taya Y, et
al: CIP2A inhibits PP2A in human malignancies. Cell. 130:51–62.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Seshacharyulu P, Pandey P, Datta K and
Batra SK: Phosphatase: PP2A structural importance, regulation and
its aberrant expression in cancer. Cancer Lett. 335:9–18. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Schönthal AH: Role of serine/threonine
protein phosphatase 2A in cancer. Cancer Lett. 170:1–13. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Lv P, Wang Y, Ma J, Wang Z, Li JL, Hong
CS, Zhuang Z and Zeng YX: Inhibition of protein phosphatase 2A with
a small molecule LB100 radiosensitizes nasopharyngeal carcinoma
xenografts by inducing mitotic catastrophe and blocking DNA damage
repair. Oncotarget. 5:7512–7524. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Li M, Makkinje A and Damuni Z: The myeloid
leukemia-associated protein SET is a potent inhibitor of protein
phosphatase 2A. J Biol Chem. 271:11059–11062. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Adachi Y, Pavlakis GN and Copeland TD:
Identification and characterization of SET, a nuclear
phosphoprotein encoded by the translocation break point in acute
undifferentiated leukemia. J Biol Chem. 269:2258–2262.
1994.PubMed/NCBI
|
|
11
|
Kalousi A, Hoffbeck AS, Selemenakis PN,
Pinder J, Savage KI, Khanna KK, Brino L, Dellaire G, Gorgoulis VG
and Soutoglou E: The nuclear oncogene SET controls DNA repair by
KAP1 and HP1 retention to chromatin. Cell Rep. 11:149–163. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Carlson SG, Eng E, Kim EG, Perlman EJ,
Copeland TD and Ballermann BJ: Expression of SET, an inhibitor of
protein phosphatase 2A, in renal development and Wilms' tumor. J Am
Soc Nephrol. 9:1873–1880. 1998.PubMed/NCBI
|
|
13
|
Bhutia YD, Hung SW, Krentz M, Patel D,
Lovin D, Manoharan R, Thomson JM and Govindarajan R: Differential
processing of let-7a precursors influences RRM2 expression and
chemosensitivity in pancreatic cancer: Role of LIN-28 and SET
oncoprotein. PLoS One. 8:e534362013. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Anazawa Y, Nakagawa H, Furihara M, Ashida
S, Tamura K, Yoshioka H, Shuin T, Fujioka T, Katagiri T and
Nakamura Y: PCOTH, a novel gene overexpressed in prostate cancers,
promotes prostate cancer cell growth through phosphorylation of
oncoprotein TAF-Ibeta/SET. Cancer Res. 65:4578–4586. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Ouellet V, Page CL, Guyot M-C, Lussier C,
Tonin PN, Provencher DM and Mes-Masson A-M: SET complex in serous
epithelial ovarian cancer. Int J Cancer. 119:2119–2126. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Liu H, Gu Y, Wang H, Yin J, Zheng G, Zhang
Z, Lu M, Wang C and He Z: Overexpression of PP2A inhibitor SET
oncoprotein is associated with tumor progression and poor prognosis
in human non-small cell lung cancer. Oncotarget. 6:14913–14925.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Cristóbal I, Garcia-Orti L, Cirauqui C,
Cortes-Lavaud X, García-Sánchez MA, Calasanz MJ and Odero MD:
Overexpression of SET is a recurrent event associated with poor
outcome and contributes to protein phosphatase 2A inhibition in
acute myeloid leukemia. Haematologica. 97:543–550. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Christensen DJ, Chen Y, Oddo J, Matta KM,
Neil J, Davis ED, Volkheimer AD, Lanasa MC, Friedman DR, Goodman
BK, et al: SET oncoprotein overexpression in B-cell chronic
lymphocytic leukemia and non-Hodgkin lymphoma: A predictor of
aggressive disease and a new treatment target. Blood.
118:4150–4158. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Cao W, Liu Y, Zhang R, Zhang B, Wang T,
Zhu X, Mei L, Chen H, Zhang H, Ming P, et al: Homoharringtonine
induces apoptosis and inhibits STAT3 via IL-6/JAK1/STAT3 signal
pathway in Gefitinib-resistant lung cancer cells. Sci Rep.
5:84772015. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Xiao X, He Z, Cao W, Cai F, Zhang L, Huang
Q, Fan C, Duan C, Wang X, Wang J, et al: Oridonin inhibits
gefitinib-resistant lung cancer cells by suppressing
EGFR/ERK/MMP-12 and CIP2A/Akt signaling pathways. Int J Oncol.
48:2608–2618. 2016.PubMed/NCBI
|
|
22
|
Khanna A, Böckelman C, Hemmes A, Junttila
MR, Wiksten JP, Lundin M, Junnila S, Murphy DJ, Evan GI, Haglund C,
et al: MYC-dependent regulation and prognostic role of CIP2A in
gastric cancer. J Natl Cancer Inst. 101:793–805. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Rincón R, Cristóbal I, Zazo S, Arpí O,
Menéndez S, Manso R, Lluch A, Eroles P, Rovira A, Albanell J, et
al: PP2A inhibition determines poor outcome and doxorubicin
resistance in early breast cancer and its activation shows
promising therapeutic effects. Oncotarget. 6:4299–4314. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Li L, Fan B, Zhang LH, Xing XF, Cheng XJ,
Wang XH, Guo T, Du H, Wen XZ and Ji JF: Trichostatin A potentiates
TRAIL-induced antitumor effects via inhibition of ERK/FOXM1 pathway
in gastric cancer. Tumour Biol. 37:10269–10278. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Liu Y, Cao W, Zhang B, Liu YQ, Wang ZY, Wu
YP, Yu XJ, Zhang XD, Ming PH, Zhou GB, et al: The natural compound
magnolol inhibits invasion and exhibits potential in human breast
cancer therapy. Sci Rep. 3:30982013. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Pippa R, Dominguez A, Christensen DJ,
Moreno-Miralles I, Blanco-Prieto MJ, Vitek MP and Odero MD: Effect
of FTY720 on the SET-PP2A complex in acute myeloid leukemia; SET
binding drugs have antagonistic activity. Leukemia. 28:1915–1918.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Agarwal A, MacKenzie RJ, Pippa R, Eide CA,
Oddo J, Tyner JW, Sears R, Vitek MP, Odero MD, Christensen DJ, et
al: Antagonism of SET using OP449 enhances the efficacy of tyrosine
kinase inhibitors and overcomes drug resistance in myeloid
leukemia. Clin Cancer Res. 20:2092–2103. 2014. View Article : Google Scholar : PubMed/NCBI
|
